Common Contracts
2 similar Agreement and Plan of Merger contracts by Sorrento Therapeutics, Inc., Vickers Vantage Corp. I
AGREEMENT AND PLAN OF MERGER by and among SCILEX HOLDING COMPANY, SIGMA MERGER SUB, INC., SEMNUR PHARMACEUTICALS, INC., FORTIS ADVISORS LLC, SOLELY AS THE EQUITYHOLDERS’ REPRESENTATIVE AND, SOLELY WITH RESPECT TO SECTION 1.8(a), SECTION 3.11 AND...Agreement and Plan of Merger • June 27th, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of March 18, 2019, by and among Scilex Holding Company, a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as representative of the Equityholders (the “Equityholders’ Representative”), and, solely with respect to Section 1.8(a), Section 3.11 and Article X (collectively, the “Specified Sections”), Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”).
AGREEMENT AND PLAN OF MERGER by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the Equityholders’ Representative and, solely with respect to Section 1.8(a), Section 3.11 and...Agreement and Plan of Merger • March 22nd, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
This AGREEMENT AND PLAN OF MERGER is made and entered into as of March 18, 2019, by and among Scilex Holding Company, a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as representative of the Equityholders (the “Equityholders’ Representative”), and, solely with respect to Section 1.8(a), Section 3.11 and Article X (collectively, the “Specified Sections”), Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”).
